Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
https://www.zacks.com/stock/news/2253502/moderna-mrna-up-6-on-upbeat-data-from-cancer-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253502
Apr 10, 2024 - Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
0
Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth
https://www.zacks.com/stock/news/2257704/merck-mrk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2257704
Apr 18, 2024 - Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
https://www.zacks.com/stock/news/2259557/how-should-you-play-merck-mrk-stock-ahead-of-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2259557
Apr 22, 2024 - Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
0